These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

467 related articles for article (PubMed ID: 32390306)

  • 21. 2016 updated EULAR evidence-based recommendations for the management of gout.
    Richette P; Doherty M; Pascual E; Barskova V; Becce F; Castañeda-Sanabria J; Coyfish M; Guillo S; Jansen TL; Janssens H; Lioté F; Mallen C; Nuki G; Perez-Ruiz F; Pimentao J; Punzi L; Pywell T; So A; Tausche AK; Uhlig T; Zavada J; Zhang W; Tubach F; Bardin T
    Ann Rheum Dis; 2017 Jan; 76(1):29-42. PubMed ID: 27457514
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Predicting Response or Non-response to Urate-Lowering Therapy in Patients with Gout.
    Graham GG; Stocker SL; Kannangara DRW; Day RO
    Curr Rheumatol Rep; 2018 Jun; 20(8):47. PubMed ID: 29931553
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Gout: A Rapid Review of Presentation, Diagnosis and Management.
    Badshah M; Nadeem I; Ahmed I; Naim T; Fanciullo J
    S D Med; 2024 Feb; 77(2):81-86. PubMed ID: 38986162
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Current management of gout: practical messages from 2016 EULAR guidelines.
    Nuki G; Doherty M; Richette P
    Pol Arch Intern Med; 2017 Apr; 127(4):267-277. PubMed ID: 28430170
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Budget Impact of Increased Use of Febuxostat in the Management of Gout: A US Health Plan Managed Care Pharmacy and Medical Costs Perspective.
    Smolen LJ; Gahn JC; Mitri G; Shiozawa A
    Clin Ther; 2016 Jul; 38(7):1710-25. PubMed ID: 27269247
    [TBL] [Abstract][Full Text] [Related]  

  • 26. New Perspectives in Rheumatology: Implications of the Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Morbidities Trial and the Associated Food and Drug Administration Public Safety Alert.
    Choi H; Neogi T; Stamp L; Dalbeth N; Terkeltaub R
    Arthritis Rheumatol; 2018 Nov; 70(11):1702-1709. PubMed ID: 29869840
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Current gout treatment and flare in South Korea: Prophylactic duration associated with fewer gout flares.
    Choi HJ; Lee CH; Lee JH; Yoon BY; Kim HA; Suh CH; Choi ST; Song JS; Joo HY; Choi SJ; Lee JS; Shin KC; Baek HJ
    Int J Rheum Dis; 2017 Apr; 20(4):497-503. PubMed ID: 25160939
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Better outcomes for patients with gout.
    Day R; Nguyen A; Graham G; Aung E; Coleshill M; Stocker S
    Inflammopharmacology; 2020 Oct; 28(5):1395-1400. PubMed ID: 32095979
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Achieving serum urate targets in gout: an audit in a gout-oriented rheumatology practice.
    Corbett EJM; Pentony P; McGill NW
    Int J Rheum Dis; 2017 Jul; 20(7):894-897. PubMed ID: 28205336
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cardiovascular effects of urate-lowering therapies in patients with chronic gout: a systematic review and meta-analysis.
    Zhang T; Pope JE
    Rheumatology (Oxford); 2017 Jul; 56(7):1144-1153. PubMed ID: 28379501
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Gout in a rheumatology clinic: results of EULAR/ACR guidelines-compliant treatment.
    Slot O
    Scand J Rheumatol; 2018 May; 47(3):194-197. PubMed ID: 28891365
    [TBL] [Abstract][Full Text] [Related]  

  • 32. 2020 Recommendations from the French Society of Rheumatology for the management of gout: Management of acute flares.
    Latourte A; Pascart T; Flipo RM; Chalès G; Coblentz-Baumann L; Cohen-Solal A; Ea HK; Grichy J; Letavernier E; Lioté F; Ottaviani S; Sigwalt P; Vandecandelaere G; Richette P; Bardin T
    Joint Bone Spine; 2020 Oct; 87(5):387-393. PubMed ID: 32422339
    [TBL] [Abstract][Full Text] [Related]  

  • 33. EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT).
    Zhang W; Doherty M; Bardin T; Pascual E; Barskova V; Conaghan P; Gerster J; Jacobs J; Leeb B; Lioté F; McCarthy G; Netter P; Nuki G; Perez-Ruiz F; Pignone A; Pimentão J; Punzi L; Roddy E; Uhlig T; Zimmermann-Gòrska I;
    Ann Rheum Dis; 2006 Oct; 65(10):1312-24. PubMed ID: 16707532
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Debates in gout management.
    Abhishek A
    Curr Opin Rheumatol; 2020 Mar; 32(2):134-139. PubMed ID: 31842034
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Stepwise dose increase of febuxostat is comparable with colchicine prophylaxis for the prevention of gout flares during the initial phase of urate-lowering therapy: results from FORTUNE-1, a prospective, multicentre randomised study.
    Yamanaka H; Tamaki S; Ide Y; Kim H; Inoue K; Sugimoto M; Hidaka Y; Taniguchi A; Fujimori S; Yamamoto T
    Ann Rheum Dis; 2018 Feb; 77(2):270-276. PubMed ID: 29102957
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Management of complex gout in clinical practice: Update on therapeutic approaches.
    Narang RK; Dalbeth N
    Best Pract Res Clin Rheumatol; 2018 Dec; 32(6):813-834. PubMed ID: 31427057
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Management of Gout and Hyperuricemia in CKD.
    Vargas-Santos AB; Neogi T
    Am J Kidney Dis; 2017 Sep; 70(3):422-439. PubMed ID: 28456346
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Advances in pharmacotherapy for the treatment of gout.
    Robinson PC; Dalbeth N
    Expert Opin Pharmacother; 2015 Mar; 16(4):533-46. PubMed ID: 25547991
    [TBL] [Abstract][Full Text] [Related]  

  • 39. An appraisal of the 2012 American College of Rheumatology Guidelines for the Management of Gout.
    Nuki G
    Curr Opin Rheumatol; 2014 Mar; 26(2):152-61. PubMed ID: 24492863
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.